Global TIL Therapies Market Report 2023 to 2035: Key Players Include Bristol-Myers Squibb, CAR-T (Shanghai) Cell Biotechnology, Cellectis and Incyte - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

The report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL therapies. The report answers many key questions related to this domain.

Over the years, various studies have validated the successful use of tumor-infiltrating lymphocytes (TILs) in treating patients diagnosed with refractory diseases. TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, NK cells and macrophages isolated from the tumor.

These lymphocytes selectively mediate the elimination of tumor cells. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various solid tumors.

Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TIL therapies market is likely to witness significant growth in the foreseen future.

Key Market Insights

This report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL therapies. The report answers many key questions related to this domain.

Need for TIL therapies for the Treatment of Various Types of Cancer

Modified tumor-infiltrating lymphocytes (TIL)-based interventions have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL therapies.

Their tumor-cell killing efficiency is attributed to the fact that they are pre-sensitized to cancer specific antigens. Additionally, this emerging class of biologics is believed to possess the potential to cater to the unmet pharmacological needs, across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate.

Current Market Landscape of TIL therapies

Over 75 TIL immunotherapies are being evaluated across different stages of preclinical / clinical development, either as monotherapies or in combination with other drugs. Both industry and non-industry players have demonstrated keen interest in the development of novel TIL-based cell therapies.

Further, melanoma emerged as the most popular target indication in this domain. More than 95% of the therapy candidates that are being developed to target a wide range of disease indications are autologous in nature.

Rising Interest in TIL therapies

A growing interest in TIL therapies is reflected from the increase in the partnerships focused on R&D of such therapies. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013.

Further, in the last 10 years, close to 95 clinical trials evaluating TIL therapies have been registered across different geographies. Mostly driven by the need for effective treatment options for cancer, the TIL therapies pipeline is expected to steadily grow over the coming years. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives.

Market Size of the TIL therapies Market

With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 40% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by therapies being developed to target melanoma and head and neck carcinoma.

Additionally, close to 90% of the market is anticipated to be captured by players based in North America and Europe, in 2035. Overall, we are led to believe that the global TIL therapies market is poised to witness significant growth in the foreseen future.

Who are the Key Players in the TIL therapies Market

Examples of key players engaged in this domain (which have also been captured in this report) include Bristol-Myers Squibb, CAR-T (Shanghai) Cell Biotechnology, Cellectis, Incyte Corporation, Instil Bio, Iovance Biotherapeutics, Lytix Biopharma, Phio Pharmaceuticals and Prometheus Laboratories.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. TIL-BASED THERAPIES: MARKET LANDSCAPE

5. CLINICAL TRIAL ANALYSIS

6. KEY OPINION LEADERS

7. TIL-BASED THERAPY PROFILES

8. PARTNERSHIPS AND COLLABORATIONS

9. FUNDING AND INVESTMENT ANALYSIS

10. PATENT ANALYSIS

11. CASE STUDY: CELL THERAPY MANUFACTURING

12. COST PRICE ANALYSIS

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

14. COMPANY PROFILES

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/llni40-til?w=4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900